SFAM
VRTX icon

Sawyer Falduto Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Sawyer Falduto Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.7K Hold
100
– – 0.04% 99
2026
Q1 		$44.7K Hold
100
– – 0.04% 105
2025
Q4 		$45.3K Buy
+100
New +$43.1K 0.04% 101

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Sawyer Falduto Asset Management's VRTX Position: Q2 2026 in Review

Sawyer Falduto Asset Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 100 shares worth $49.7K. The position accounts for 0.04% of the portfolio, ranked #99.

Sawyer Falduto Asset Management first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Sawyer Falduto Asset Management held 100 shares of Vertex Pharmaceuticals worth $49.7K as of Q2 2026.
  • Sawyer Falduto Asset Management left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up 0.04% of Sawyer Falduto Asset Management's portfolio in Q2 2026, its #99 holding.
  • Sawyer Falduto Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Sawyer Falduto Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.